公开(公告)号：CA2161256C

公开(公告)日：2004-06-29

申请号：CA2161256

申请日：1994-04-25

Applicant: SEPRACOR INC

Inventor： GRAY NANCY M

IPC: C07D401/12 ,  A61K31/44 ,  A61K31/4427 ,  A61K31/4439 ,  A61P1/04

Abstract: Methods and compositions are disclosed utilizing optically pure (-) pantoprazole for the treatment of ulcers in humans while substantially reducing the concomitant liability of adverse effects associated with the racemic mixture of pantoprazole. The optically pure (-) isomer is also useful for the treatment of gastroesophageal reflux. (-) Pantoprazole is an inhibitor of H+ release and is therefore useful in the treatment of other conditions related to gastric hypersecretion such as Zollinger-Ellison Syndrome.

公开(公告)号：NO310644B1

公开(公告)日：2001-08-06

申请号：NO950374

申请日：1995-02-01

Applicant: SEPRACOR INC

Inventor： YOUNG JAMES W ,  GRAY NANCY M ,  WOOSLEY RAYMOND L ,  CHEN YIWANG

IPC: A61K9/48 ,  A61K31/137 ,  C07D211/22 ,  A61K31/165 ,  A61K31/192 ,  A61K31/445 ,  A61K31/451 ,  A61K31/60 ,  A61K45/00 ,  A61K45/06 ,  A61P17/00 ,  A61P27/16 ,  A61P37/08 ,  A61P43/00

Abstract: Use of a composition comprising a compound of formula I: or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for use in providing symptomatic relief from dermal irritation, wherein the induction of cardiac arrhythmia is avoided, said treatment comprising administering a therapeutically effective amount of a compound of formula I to a human patient whose hepatic function is not impaired.

公开(公告)号：AT193648T

公开(公告)日：2000-06-15

申请号：AT93907465

申请日：1993-03-12

Applicant: SEPRACOR INC

Inventor： YOUNG JAMES W ,  GRAY NANCY M ,  WECHTER WILLIAM J

IPC: C07D491/052 ,  A61K31/40 ,  A61P25/04

Abstract: Methods are disclosed utilizing optically pure R(-) etodolac for the treatment of pain, including but not limited to pain associated with toothaches, headaches, sprains, joint pain and surgical pain, for example dental pain and ophthalmic pain, while substantially reducing adverse effects which are associated with the administration of the racemic mixture of etodolac. The optically pure R(-) etodolac is also useful in treating pyrexia while substantially reducing the adverse effects associated with the administration of the racemic mixture of etodolac.

公开(公告)号：AU711212B2

公开(公告)日：1999-10-07

申请号：AU5934398

申请日：1998-03-17

Applicant: SEPRACOR INC

Inventor： GRAY NANCY M

IPC: C07D241/04 ,  A61K31/495 ,  A61P11/00 ,  A61P37/08

公开(公告)号：DK0661975T3

公开(公告)日：1999-09-27

申请号：DK94910260

申请日：1993-09-22

Applicant: SEPRACOR INC

Inventor： GRAY NANCY M

IPC: C07D241/04 ,  A61K31/495 ,  A61P11/00 ,  A61P37/08

公开(公告)号：ES2128556T3

公开(公告)日：1999-05-16

申请号：ES94910260

申请日：1993-09-22

Applicant: SEPRACOR INC

Inventor： GRAY NANCY M

IPC: C07D241/04 ,  A61K31/495 ,  A61P11/00 ,  A61P37/08

公开(公告)号：AT170749T

公开(公告)日：1998-09-15

申请号：AT93921715

申请日：1993-09-22

Applicant: SEPRACOR INC

Inventor： GRAY NANCY M

IPC: C07D241/04 ,  A61K31/495 ,  A61P11/00 ,  A61P37/08

公开(公告)号：AU6904498A

公开(公告)日：1998-07-16

申请号：AU6904498

申请日：1998-05-28

Applicant: SEPRACOR INC

Inventor： GRAY NANCY M

IPC: C07D401/12 ,  A61K31/44 ,  A61K31/4427 ,  A61K31/4439 ,  A61P1/04

公开(公告)号：AU6374798A

公开(公告)日：1998-06-18

申请号：AU6374798

申请日：1998-04-30

Applicant: SEPRACOR INC

Inventor： GRAY NANCY M

IPC: C07D405/12 ,  A61K9/20 ,  A61K9/48 ,  A61K31/496 ,  A61K31/505 ,  A61K31/517 ,  A61P9/10 ,  A61P13/08 ,  A61P35/00 ,  C07D237/10

公开(公告)号：ES2086270T3

公开(公告)日：1998-03-01

申请号：ES93918584

申请日：1993-08-03

Applicant: SEPRACOR INC ,  UNIV GEORGETOWN

Inventor： YOUNG JAMES W ,  GRAY NANCY M ,  WOOSLEY RAYMOND L ,  CHEN YIWANG

IPC: A61K9/48 ,  C07D211/22 ,  A61K31/137 ,  A61K31/165 ,  A61K31/192 ,  A61K31/445 ,  A61K31/451 ,  A61K31/60 ,  A61K45/00 ,  A61K45/06 ,  A61P17/00 ,  A61P27/16 ,  A61P37/08 ,  A61P43/00

Abstract: Use of a composition comprising a compound of formula I: or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for use in providing symptomatic relief from dermal irritation, wherein the induction of cardiac arrhythmia is avoided, said treatment comprising administering a therapeutically effective amount of a compound of formula I to a human patient whose hepatic function is not impaired.